Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viral hepatitis.

S Sherlock

    Digestive Diseases and Sciences
    |September 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Recent viral hepatitis research advances include hepatitis A vaccines and new hepatitis B therapies. Delta virus is a significant threat to hepatitis B carriers, while non-A, non-B agents remain unidentified.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis.

    Clinics in liver disease·2001
    Same author

    A la carte interferon for hepatitis C?

    Hepatology (Baltimore, Md.)·2000
    Same author

    The hepatic flaviviridae: summary.

    Journal of viral hepatitis·2000
    Same author

    Biotechnologies and liver diseases.

    Forum (Genoa, Italy)·1999
    Same author

    Carbon dioxide embolism following diagnostic hysteroscopy.

    Anaesthesia and intensive care·1999
    Same author

    Focal nodular hyperplasia in a young female.

    Journal of hepatology·1999
    Same journal

    Prevalence and Impact of Protein-Calorie Malnutrition in Hospitalized Patients with Steatotic Liver Disease.

    Digestive diseases and sciences·2026
    Same journal

    Development and Validation of a Crotonylation-Related Prognostic Risk Model for Cholangiocarcinoma Based on Integrative Transcriptome Analysis.

    Digestive diseases and sciences·2026
    Same journal

    Cardiac Arrests During Inpatient Gastrointestinal Endoscopic Procedures: A United States Nationwide Assessment.

    Digestive diseases and sciences·2026
    Same journal

    Standardizing Transition of Care for Adolescents with Inflammatory Bowel Disease: The Need for a Unified Approach.

    Digestive diseases and sciences·2026
    Same journal

    Rapid Gastric Emptying: Insights from a Large Cohort Study on a Controversial Disorder.

    Digestive diseases and sciences·2026
    Same journal

    Readability, Quality, Understandability, and Actionability of ChatGPT Generated GI Patient Education Versus AGA Patient Center.

    Digestive diseases and sciences·2026
    See all related articles

    Area of Science:

    • Hepatology and Virology

    Background:

    • Viral hepatitis encompasses several distinct infectious diseases affecting the liver.
    • Significant advancements in understanding and managing viral hepatitis have occurred in recent years.

    Purpose of the Study:

    • To analyze recent developments in the understanding and management of viral hepatitis.
    • To highlight progress in vaccine development and therapeutic strategies.

    Main Methods:

    • Review of scientific literature and clinical data over the past four years.
    • Analysis of molecular structures, disease stages, and etiological agents.

    Main Results:

    • Hepatitis A: molecular structure elucidated, vaccines in development.
    • Hepatitis B: understanding replicative and integrated stages aids therapy; vaccines proven effective.

    Related Experiment Videos

  • Hepatitis Delta: recognized as a significant cause of severe liver disease in hepatitis B carriers.
  • Non-A, Non-B Hepatitis: causative agents remain unidentified but are linked to chronic liver disease, especially post-transfusion.

    • Conclusions:

    • Vaccine development for Hepatitis A shows promise.
    • Therapeutic approaches for Hepatitis B are becoming more rational.
    • Hepatitis Delta poses a global health challenge for Hepatitis B carriers.
    • Identification of non-A, non-B hepatitis agents is crucial for preventing chronic liver disease.